Skip to content
Baret News – Lifestyle
Author:
Opus Genetics, Inc.
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
May 7, 2026
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
May 4, 2026
←
Previous Page
1
2
3